Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.54 |
| ▸ | PLAU | P00749 | 3/20 | 0.53 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.50 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | PLG | P00747 | 1/20 | 0.50 |
| ▸ | PLAT | P00750 | 1/20 | 0.50 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.50 |
| ▸ | KLK1 | P06870 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14111903 | 0.87 | MEN1 (0.70) | KMT2AMEN1NPC1RAB9AHPSE | |
| SCHEMBL7325287 | 0.86 | KMT2A (0.78) | KMT2AMEN1NPC1RAB9AHPSE | |
| SCHEMBL6078756 | 0.86 | PLAU (0.71) | KMT2AMEN1NPC1RAB9APLAU | |
| SCHEMBL6865518 | 0.86 | HPSE (0.72) | KMT2AMEN1RAB9AHPSEPKM | |
| SCHEMBL13381189 | 0.86 | MEN1 (0.67) | KMT2AMEN1NPC1RAB9AHPSE | |
| SCHEMBL6079483 | 0.85 | HPSE (0.76) | KMT2AMEN1NPC1RAB9AHPSE | |
| SCHEMBL19829336 | 0.83 | PTGS1 (0.65) | KMT2AMEN1HPSEPKML3MBTL1 | |
| SCHEMBL13381198 | 0.81 | L3MBTL1 (0.82) | KMT2AMEN1NPC1RAB9AHPSE | |
| SCHEMBL9249052 | 0.81 | HPSE (0.84) | KMT2AMEN1NPC1RAB9AHPSE | |
| SCHEMBL437116 | 0.81 | KDM4E (0.48) | KMT2AMEN1NPC1RAB9APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071231-B2 | Naphthalene ureas as glucose uptake enhancers | TELIK, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1181271-B1 | NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS | TELIK INC (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20030135063-A1 | Novel naphthalene ureas as glucose uptake enhancers | SPEVAK WAYNE R (US) | 2003-07-17 | — | — | US | disclosed |
| US-6458998-B1 | NAPHTHALENEUREAS AS ANTIDIABETIC AGENTS | TELIK, INC. | 2002-10-01 | — | — | US | disclosed |
| EP-1181271-A2 | NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS | Telik, Inc. (US) | 2002-02-27 | — | — | EP | disclosed |
| WO-2000071506-A9 | NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS | TELIK INC (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2000071506-A2 | NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS | TELIK, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030135063-A1 | Novel naphthalene ureas as glucose uptake enhancers | GPR119, SLC2A8, SLC2A1 | KMT2A 4632/4885MEN1 3696/4885NPC1 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.